Thermo Fisher Scientific Inc. Logo

Thermo Fisher Scientific Inc.

TMO

(2.2)
Stock Price

513,08 USD

15.9% ROA

13.45% ROE

36.56x PER

Market Cap.

227.459.518.200,00 USD

74.64% DER

0.26% Yield

14.69% NPM

Thermo Fisher Scientific Inc. Stock Analysis

Thermo Fisher Scientific Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Thermo Fisher Scientific Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

2 Dividend Growth

Investors can take confidence in the company's impressive track record of annual dividend growth over the last five years, showcasing a commitment to rewarding shareholders.

3 Dividend

The company's consistent dividend payouts over the past five years exemplify its strong commitment to providing shareholders with reliable returns, making it an attractive investment option.

4 ROE

ROE in an average range (13.54%) suggests satisfactory profitability and decent utilization of shareholders' equity.

5 DER

The stock maintains a fair debt to equity ratio (78%), indicating a reasonable balance between the money it owes and the ownership it possesses.

6 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (4.147), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

7 PBV

The stock's elevated P/BV ratio (3.97x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

8 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

10 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

11 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

Thermo Fisher Scientific Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Thermo Fisher Scientific Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Thermo Fisher Scientific Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Thermo Fisher Scientific Inc. Revenue
Year Revenue Growth
1985 265.700.000
1986 331.600.000 19.87%
1987 383.400.000 13.51%
1988 500.600.000 23.41%
1989 579.000.000 13.54%
1990 708.000.000 18.22%
1991 805.500.000 12.1%
1992 949.000.000 15.12%
1993 1.249.700.000 24.06%
1994 1.585.300.000 21.17%
1995 2.207.400.000 28.18%
1996 2.932.600.000 24.73%
1997 3.558.300.000 17.58%
1998 3.867.600.000 8%
1999 2.471.200.000 -56.51%
2000 2.280.522.000 -8.36%
2001 2.188.210.000 -4.22%
2002 2.086.355.000 -4.88%
2003 2.097.135.000 0.51%
2004 2.205.995.000 4.93%
2005 2.633.027.000 16.22%
2006 3.791.617.000 30.56%
2007 9.746.400.000 61.1%
2008 10.498.000.000 7.16%
2009 10.109.700.000 -3.84%
2010 10.788.700.000 6.29%
2011 11.725.900.000 7.99%
2012 12.509.900.000 6.27%
2013 13.090.300.000 4.43%
2014 16.889.600.000 22.49%
2015 16.965.400.000 0.45%
2016 18.274.100.000 7.16%
2017 20.918.000.000 12.64%
2018 24.358.000.000 14.12%
2019 25.542.000.000 4.64%
2020 32.218.000.000 20.72%
2021 39.211.000.000 17.83%
2022 44.915.000.000 12.7%
2023 42.296.000.000 -6.19%
2023 42.857.000.000 1.31%
2024 42.164.000.000 -1.64%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Thermo Fisher Scientific Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 103.700.000 100%
1995 269.600.000 61.54%
1996 0 0%
1997 337.300.000 100%
1998 367.300.000 8.17%
1999 171.100.000 -114.67%
2000 176.756.000 3.2%
2001 171.614.000 -3%
2002 155.121.000 -10.63%
2003 146.394.000 -5.96%
2004 134.680.000 -8.7%
2005 152.775.000 11.84%
2006 170.184.000 10.23%
2007 238.700.000 28.7%
2008 249.100.000 4.18%
2009 246.100.000 -1.22%
2010 287.200.000 14.31%
2011 340.600.000 15.68%
2012 376.400.000 9.51%
2013 395.500.000 4.83%
2014 691.100.000 42.77%
2015 692.300.000 0.17%
2016 754.800.000 8.28%
2017 888.000.000 15%
2018 967.000.000 8.17%
2019 1.003.000.000 3.59%
2020 1.181.000.000 15.07%
2021 1.406.000.000 16%
2022 1.471.000.000 4.42%
2023 1.276.000.000 -15.28%
2023 1.337.000.000 4.56%
2024 1.356.000.000 1.4%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Thermo Fisher Scientific Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Thermo Fisher Scientific Inc. EBITDA
Year EBITDA Growth
1985 1.200.000
1986 11.400.000 89.47%
1987 -7.100.000 260.56%
1988 9.800.000 172.45%
1989 -800.000 1325%
1990 17.900.000 104.47%
1991 2.400.000 -645.83%
1992 39.500.000 93.92%
1993 158.500.000 75.08%
1994 158.800.000 0.19%
1995 203.200.000 21.85%
1996 308.900.000 34.22%
1997 461.400.000 33.05%
1998 522.400.000 11.68%
1999 573.300.000 8.88%
2000 308.975.000 -85.55%
2001 361.648.000 14.56%
2002 193.079.000 -87.31%
2003 306.881.000 37.08%
2004 313.604.000 2.14%
2005 383.170.000 18.16%
2006 573.063.000 33.14%
2007 1.818.000.000 68.48%
2008 2.094.500.000 13.2%
2009 1.913.100.000 -9.48%
2010 2.107.800.000 9.24%
2011 2.236.000.000 5.73%
2012 2.576.800.000 13.23%
2013 2.659.200.000 3.1%
2014 3.653.700.000 27.22%
2015 4.154.800.000 12.06%
2016 4.440.700.000 6.44%
2017 5.151.000.000 13.79%
2018 6.246.000.000 17.53%
2019 6.610.000.000 5.51%
2020 10.202.000.000 35.21%
2021 12.166.000.000 16.14%
2022 12.056.000.000 -0.91%
2023 12.244.000.000 1.54%
2023 10.724.000.000 -14.17%
2024 10.192.000.000 -5.22%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Thermo Fisher Scientific Inc. Gross Profit
Year Gross Profit Growth
1985 91.400.000
1986 112.300.000 18.61%
1987 134.700.000 16.63%
1988 174.900.000 22.98%
1989 194.900.000 10.26%
1990 265.000.000 26.45%
1991 295.300.000 10.26%
1992 369.200.000 20.02%
1993 536.600.000 31.2%
1994 719.000.000 25.37%
1995 1.082.700.000 33.59%
1996 1.390.100.000 22.11%
1997 1.720.700.000 19.21%
1998 1.843.000.000 6.64%
1999 1.206.300.000 -52.78%
2000 1.021.836.000 -18.05%
2001 958.622.000 -6.59%
2002 927.376.000 -3.37%
2003 948.015.000 2.18%
2004 1.014.479.000 6.55%
2005 1.194.948.000 15.1%
2006 1.568.060.000 23.79%
2007 3.804.400.000 58.78%
2008 4.206.200.000 9.55%
2009 4.149.400.000 -1.37%
2010 4.573.600.000 9.27%
2011 4.988.600.000 8.32%
2012 5.516.900.000 9.58%
2013 5.751.100.000 4.07%
2014 7.919.000.000 27.38%
2015 8.182.700.000 3.22%
2016 8.815.000.000 7.17%
2017 9.957.000.000 11.47%
2018 11.364.000.000 12.38%
2019 11.827.000.000 3.91%
2020 16.505.000.000 28.34%
2021 20.234.000.000 18.43%
2022 19.500.000.000 -3.76%
2023 17.716.000.000 -10.07%
2023 15.224.000.000 -16.37%
2024 17.376.000.000 12.38%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Thermo Fisher Scientific Inc. Net Profit
Year Net Profit Growth
1985 9.600.000
1986 14.300.000 32.87%
1987 18.100.000 20.99%
1988 20.100.000 9.95%
1989 24.600.000 18.29%
1990 33.900.000 27.43%
1991 47.100.000 28.03%
1992 59.200.000 20.44%
1993 76.600.000 22.72%
1994 103.400.000 25.92%
1995 140.100.000 26.2%
1996 190.800.000 26.57%
1997 239.300.000 20.27%
1998 181.900.000 -31.56%
1999 -174.600.000 204.18%
2000 -36.111.000 -383.51%
2001 -781.000 -4523.69%
2002 309.730.000 100.25%
2003 200.009.000 -54.86%
2004 361.837.000 44.72%
2005 223.218.000 -62.1%
2006 168.935.000 -32.13%
2007 761.100.000 77.8%
2008 994.200.000 23.45%
2009 850.300.000 -16.92%
2010 1.035.600.000 17.89%
2011 1.329.900.000 22.13%
2012 1.177.900.000 -12.9%
2013 1.273.300.000 7.49%
2014 1.894.400.000 32.79%
2015 1.975.400.000 4.1%
2016 2.021.800.000 2.29%
2017 2.225.000.000 9.13%
2018 2.938.000.000 24.27%
2019 3.696.000.000 20.51%
2020 6.375.000.000 42.02%
2021 7.725.000.000 17.48%
2022 6.950.000.000 -11.15%
2023 6.860.000.000 -1.31%
2023 5.995.000.000 -14.43%
2024 6.192.000.000 3.18%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Thermo Fisher Scientific Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 1 0%
1995 1 100%
1996 1 0%
1997 2 0%
1998 1 0%
1999 -1 200%
2000 0 0%
2001 0 0%
2002 2 100%
2003 1 0%
2004 2 50%
2005 1 -100%
2006 1 0%
2007 2 100%
2008 2 50%
2009 2 0%
2010 3 0%
2011 3 33.33%
2012 3 0%
2013 4 0%
2014 5 25%
2015 5 0%
2016 5 20%
2017 6 0%
2018 7 28.57%
2019 9 22.22%
2020 16 43.75%
2021 20 15.79%
2022 18 -11.76%
2023 18 0%
2023 16 -13.33%
2024 16 6.25%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Thermo Fisher Scientific Inc. Free Cashflow
Year Free Cashflow Growth
1989 -300.000
1990 -101.400.000 99.7%
1991 -10.500.000 -865.71%
1992 -5.100.000 -105.88%
1993 70.100.000 107.28%
1994 144.000.000 51.32%
1995 131.700.000 -9.34%
1996 100.000.000 -31.7%
1997 -691.700.000 114.46%
1998 -72.700.000 -851.44%
1999 -150.879.000 51.82%
2000 125.882.000 219.86%
2001 103.602.000 -21.51%
2002 51.680.000 -100.47%
2003 170.583.000 69.7%
2004 214.525.000 20.48%
2005 227.368.000 5.65%
2006 328.857.000 30.86%
2007 1.308.000.000 74.86%
2008 1.155.800.000 -13.17%
2009 1.451.700.000 20.38%
2010 1.232.300.000 -17.8%
2011 1.424.500.000 13.49%
2012 1.724.400.000 17.39%
2013 1.728.300.000 0.23%
2014 2.192.000.000 21.15%
2015 2.394.000.000 8.44%
2016 2.711.900.000 11.72%
2017 3.497.000.000 22.45%
2018 3.785.000.000 7.61%
2019 4.047.000.000 6.47%
2020 6.815.000.000 40.62%
2021 7.020.000.000 2.92%
2022 6.911.000.000 -1.58%
2023 6.927.000.000 0.23%
2023 2.082.000.000 -232.71%
2024 1.659.000.000 -25.5%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Thermo Fisher Scientific Inc. Operating Cashflow
Year Operating Cashflow Growth
1989 47.600.000
1990 18.600.000 -155.91%
1991 23.000.000 19.13%
1992 54.900.000 58.11%
1993 126.700.000 56.67%
1994 204.200.000 37.95%
1995 194.600.000 -4.93%
1996 224.500.000 13.32%
1997 269.000.000 16.54%
1998 328.500.000 18.11%
1999 337.121.000 2.56%
2000 199.921.000 -68.63%
2001 188.401.000 -6.11%
2002 102.892.000 -83.11%
2003 216.719.000 52.52%
2004 264.510.000 18.07%
2005 270.913.000 2.36%
2006 405.654.000 33.22%
2007 1.483.500.000 72.66%
2008 1.420.200.000 -4.46%
2009 1.659.200.000 14.4%
2010 1.497.800.000 -10.78%
2011 1.691.000.000 11.43%
2012 2.039.500.000 17.09%
2013 2.010.700.000 -1.43%
2014 2.619.600.000 23.24%
2015 2.816.900.000 7%
2016 3.156.300.000 10.75%
2017 4.005.000.000 21.19%
2018 4.543.000.000 11.84%
2019 4.973.000.000 8.65%
2020 8.289.000.000 40%
2021 9.543.000.000 13.14%
2022 9.154.000.000 -4.25%
2023 8.406.000.000 -8.9%
2023 2.414.000.000 -248.22%
2024 1.960.000.000 -23.16%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Thermo Fisher Scientific Inc. Capital Expenditure
Year Capital Expenditure Growth
1989 47.900.000
1990 120.000.000 60.08%
1991 33.500.000 -258.21%
1992 60.000.000 44.17%
1993 56.600.000 -6.01%
1994 60.200.000 5.98%
1995 62.900.000 4.29%
1996 124.500.000 49.48%
1997 960.700.000 87.04%
1998 401.200.000 -139.46%
1999 488.000.000 17.79%
2000 74.039.000 -559.11%
2001 84.799.000 12.69%
2002 51.212.000 -65.58%
2003 46.136.000 -11%
2004 49.985.000 7.7%
2005 43.545.000 -14.79%
2006 76.797.000 43.3%
2007 175.500.000 56.24%
2008 264.400.000 33.62%
2009 207.500.000 -27.42%
2010 265.500.000 21.85%
2011 266.500.000 0.38%
2012 315.100.000 15.42%
2013 282.400.000 -11.58%
2014 427.600.000 33.96%
2015 422.900.000 -1.11%
2016 444.400.000 4.84%
2017 508.000.000 12.52%
2018 758.000.000 32.98%
2019 926.000.000 18.14%
2020 1.474.000.000 37.18%
2021 2.523.000.000 41.58%
2022 2.243.000.000 -12.48%
2023 1.479.000.000 -51.66%
2023 332.000.000 -345.48%
2024 301.000.000 -10.3%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Thermo Fisher Scientific Inc. Equity
Year Equity Growth
1985 101.600.000
1986 145.800.000 30.32%
1987 161.800.000 9.89%
1988 181.500.000 10.85%
1989 262.200.000 30.78%
1990 399.800.000 34.42%
1991 609.000.000 34.35%
1992 722.700.000 15.73%
1993 1.150.700.000 37.19%
1994 1.318.000.000 12.69%
1995 1.771.600.000 25.6%
1996 2.438.100.000 27.34%
1997 2.717.600.000 10.28%
1998 2.897.400.000 6.21%
1999 2.386.000.000 -21.43%
2000 2.558.737.000 6.75%
2001 1.914.901.000 -33.62%
2002 2.033.323.000 5.82%
2003 2.382.806.000 14.67%
2004 2.665.550.000 10.61%
2005 2.793.312.000 4.57%
2006 13.911.827.000 79.92%
2007 14.488.300.000 3.98%
2008 14.926.600.000 2.94%
2009 15.430.900.000 3.27%
2010 15.361.000.000 -0.46%
2011 15.038.100.000 -2.15%
2012 15.464.700.000 2.76%
2013 16.856.099.999 8.25%
2014 20.548.100.000 17.97%
2015 21.350.200.000 3.76%
2016 21.540.000.000 0.88%
2017 25.413.000.000 15.24%
2018 27.586.000.000 7.88%
2019 29.675.000.000 7.04%
2020 34.517.000.000 14.03%
2021 40.977.000.000 15.76%
2022 44.148.000.000 7.18%
2023 45.464.000.000 2.89%
2023 46.842.000.000 2.94%
2024 47.535.000.000 1.46%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Thermo Fisher Scientific Inc. Assets
Year Assets Growth
1985 221.700.000
1986 308.900.000 28.23%
1987 426.100.000 27.51%
1988 490.100.000 13.06%
1989 623.600.000 21.41%
1990 898.200.000 30.57%
1991 1.199.500.000 25.12%
1992 1.818.300.000 34.03%
1993 2.473.700.000 26.49%
1994 3.019.900.000 18.09%
1995 3.744.900.000 19.36%
1996 5.141.200.000 27.16%
1997 5.795.900.000 11.3%
1998 6.331.600.000 8.46%
1999 5.181.800.000 -22.19%
2000 4.862.977.000 -6.56%
2001 3.825.070.000 -27.13%
2002 3.647.062.000 -4.88%
2003 3.388.969.000 -7.62%
2004 3.576.725.000 5.25%
2005 4.251.569.000 15.87%
2006 21.262.238.000 80%
2007 21.207.400.000 -0.26%
2008 21.090.000.000 -0.56%
2009 21.600.800.000 2.36%
2010 21.386.800.000 -1%
2011 26.833.700.000 20.3%
2012 27.444.600.000 2.23%
2013 31.863.400.000 13.87%
2014 42.852.100.000 25.64%
2015 40.834.300.000 -4.94%
2016 45.908.000.000 11.05%
2017 56.669.000.000 18.99%
2018 56.232.000.000 -0.78%
2019 58.381.000.000 3.68%
2020 69.052.000.000 15.45%
2021 95.123.000.000 27.41%
2022 97.154.000.000 2.09%
2023 97.057.000.000 -0.1%
2023 98.726.000.000 1.69%
2024 98.496.000.000 -0.23%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Thermo Fisher Scientific Inc. Liabilities
Year Liabilities Growth
1985 120.100.000
1986 163.100.000 26.36%
1987 264.300.000 38.29%
1988 308.600.000 14.36%
1989 361.400.000 14.61%
1990 498.400.000 27.49%
1991 590.500.000 15.6%
1992 1.095.600.000 46.1%
1993 1.323.000.000 17.19%
1994 1.701.900.000 22.26%
1995 1.955.900.000 12.99%
1996 2.626.200.000 25.52%
1997 2.985.100.000 12.02%
1998 3.339.800.000 10.62%
1999 2.795.300.000 -19.48%
2000 2.304.264.000 -21.31%
2001 1.910.027.000 -20.64%
2002 1.613.739.000 -18.36%
2003 1.006.163.000 -60.39%
2004 911.175.000 -10.42%
2005 1.458.257.000 37.52%
2006 7.350.411.000 80.16%
2007 6.719.100.000 -9.4%
2008 6.163.400.000 -9.02%
2009 6.169.900.000 0.11%
2010 6.025.800.000 -2.39%
2011 11.795.600.000 48.91%
2012 11.979.900.000 1.54%
2013 15.007.300.000 20.17%
2014 22.304.000.000 32.71%
2015 19.484.100.000 -14.47%
2016 24.368.000.000 20.04%
2017 31.256.000.000 22.04%
2018 28.646.000.000 -9.11%
2019 28.706.000.000 0.21%
2020 34.535.000.000 16.88%
2021 54.146.000.000 36.22%
2022 53.006.000.000 -2.15%
2023 51.593.000.000 -2.74%
2023 51.884.000.000 0.56%
2024 50.963.000.000 -1.81%

Thermo Fisher Scientific Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
110.85
Net Income per Share
16.29
Price to Earning Ratio
36.56x
Price To Sales Ratio
5.37x
POCF Ratio
24.33
PFCF Ratio
28.56
Price to Book Ratio
4.8
EV to Sales
6.04
EV Over EBITDA
25.53
EV to Operating CashFlow
27.36
EV to FreeCashFlow
32.12
Earnings Yield
0.03
FreeCashFlow Yield
0.04
Market Cap
227,46 Bil.
Enterprise Value
255,78 Bil.
Graham Number
213.3
Graham NetNet
-84.97

Income Statement Metrics

Net Income per Share
16.29
Income Quality
1.51
ROE
0.13
Return On Assets
0.06
Return On Capital Employed
0.09
Net Income per EBT
0.91
EBT Per Ebit
0.95
Ebit per Revenue
0.17
Effective Tax Rate
0.05

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.03
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.41
Operating Profit Margin
0.17
Pretax Profit Margin
0.16
Net Profit Margin
0.15

Dividends

Dividend Yield
0
Dividend Yield %
0.26
Payout Ratio
0.09
Dividend Per Share
1.52

Operating Metrics

Operating Cashflow per Share
24.47
Free CashFlow per Share
20.85
Capex to Operating CashFlow
0.15
Capex to Revenue
0.03
Capex to Depreciation
0.42
Return on Invested Capital
0.08
Return on Tangible Assets
0.16
Days Sales Outstanding
81.28
Days Payables Outstanding
37.4
Days of Inventory on Hand
76.32
Receivables Turnover
4.49
Payables Turnover
9.76
Inventory Turnover
4.78
Capex per Share
3.63

Balance Sheet

Cash per Share
23,13
Book Value per Share
124,43
Tangible Book Value per Share
-30.97
Shareholders Equity per Share
124.17
Interest Debt per Share
94.48
Debt to Equity
0.75
Debt to Assets
0.36
Net Debt to EBITDA
2.83
Current Ratio
1.72
Tangible Asset Value
-11,83 Bil.
Net Current Asset Value
-25,49 Bil.
Invested Capital
79348000000
Working Capital
10,70 Bil.
Intangibles to Total Assets
0.6
Average Receivables
9,39 Bil.
Average Payables
2,55 Bil.
Average Inventory
5165500000
Debt to Market Cap
0.16

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Thermo Fisher Scientific Inc. Dividends
Year Dividends Growth
1993 0
1996 0 0%
2001 3 100%
2012 1 0%
2013 1 0%
2014 1 0%
2015 1 0%
2016 1 0%
2017 1 0%
2018 1 0%
2019 1 0%
2020 1 0%
2021 1 100%
2022 1 0%
2023 1 0%
2024 1 0%

Thermo Fisher Scientific Inc. Profile

About Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

CEO
Mr. Marc N. Casper
Employee
122.000
Address
168 Third Avenue
Waltham, 02451

Thermo Fisher Scientific Inc. Executives & BODs

Thermo Fisher Scientific Inc. Executives & BODs
# Name Age
1 Mr. Gianluca Pettiti
Executive Vice President
70
2 Mr. Marc N. Casper
Chairman, President & Chief Executive Officer
70
3 Ms. Lisa P. Britt
Chief Human Resources Officer & Senior Vice President
70
4 Mr. Joseph R. Holmes
Vice President & Chief Accounting Officer
70
5 Mr. Ryan J. Snyder
Senior Vice President & Chief Information Officer
70
6 Dr. Karen E. Nelson Ph.D.
Chief Scientific Officer
70
7 Mr. Rafael Tejada
Vice President of Investor Relations
70
8 Mr. Michael A. Boxer Esq.
Senior Vice President & General Counsel
70
9 Mr. Stephen Williamson
Senior Vice President & Chief Financial Officer
70
10 Mr. Michel Lagarde
Executive Vice President & Chief Operating Officer
70

Thermo Fisher Scientific Inc. Competitors